Odds ratios of clinical and microbiologic outcomes with telavancin versus vancomycin in cSSTIs.
- Konstantinos A. Polyzos (220147)
- Michael N. Mavros (220129)
- Konstantinos Z. Vardakas (289355)
- Marinos C. Makris (311216)
- Petros I. Rafailidis (311217)
- Matthew E. Falagas (96197)
Publication date
February 2013
DOIAbstract
<p>Panel A: Clinical response in the intention-to-treat population. Panel B: Clinical response in the clinically evaluable population. Panel C: Clinical response in the microbiologically evaluable population with MRSA infection. Panel D: MRSA eradication.</p
Add to ORKG